New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
07:08 EDTQUREuniQure appoints Eric Goossens as COO, announces departure of CFO Piers Morgan
uniQure N.V. announced the appointment of Eric Goossens as its new COO with a primary responsibility for manufacturing and project management. Eric Goossens joins uniQure from Dätwyler Pharma Packaging Belgium N.V. Additionally, the company announced the departure of Piers Morgan, current CFO, as of May 20, when he returns to the UK to pursue other interests. uniQure announced that it has initiated the search for a new CFO.
News For QURE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
16:10 EDTQUREPoint72 Asset reports 5.0% passive stake in uniQure
Subscribe for More Information
08:50 EDTQUREuniQure price target lowered to $44 from $50 at Leerink
Leerink lowered its price target to $44 from $50 on uniQure after the company's Q2 report and pipeline update, noting that management said it is reassessing its development options for Glybera in the U.S. after the FDA said another trial would be required to support BLA filing. The firm said the company's key pipeline programs are on track, with initial data from hemophilia B and Sanfilippo B phase 1 trials expected in the second half, and keeps its Outperform rating on uniQure shares.
08:21 EDTQUREuniQure likely to delay Glybera U.S. registration indefinitely, says WallachBeth
Subscribe for More Information
07:25 EDTQUREuniQure weakness creates buying opportunity, says H.C. Wainwright
After uniQure reported a lower than expected per share loss, H.C. Wainwright believes that Hemphilia B is a key value driver for the stock. The firm notes that in a previous Phase 1 trial the same gene cassette being used by the company in an upcoming trial demonstrated continuous expression greater than 5% at the high dose and improved median bleeding episodes by 90%. The firm thinks that the stock should rise sharply if the current trial yields similar results. It keeps a $39 price target and Buy rating on the shares.
August 27, 2015
05:36 EDTQUREuniQure reports Q2 EPS (EUR 87c) vs. (EUR 51c) last year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use